Canada Pension Plan Investment Board Makes New $26.48 Million Investment in DaVita Inc. $DVA

Canada Pension Plan Investment Board bought a new position in DaVita Inc. (NYSE:DVA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 119,024 shares of the company’s stock, valued at approximately $26,480,000. Canada Pension Plan Investment Board owned about 0.19% of DaVita as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in DVA. NewEdge Advisors LLC boosted its holdings in DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after buying an additional 88 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after acquiring an additional 28,739 shares during the period. Cerity Partners LLC raised its holdings in DaVita by 7.0% in the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock worth $376,000 after purchasing an additional 172 shares during the period. Bank of Nova Scotia boosted its position in DaVita by 3.8% during the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock worth $686,000 after purchasing an additional 176 shares in the last quarter. Finally, Natixis increased its position in shares of DaVita by 80.9% in the second quarter. Natixis now owns 7,297 shares of the company’s stock valued at $1,039,000 after buying an additional 3,264 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.90% of the stock is owned by company insiders.

DaVita Price Performance

Shares of NYSE DVA opened at $180.72 on Friday. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $247.49. The company has a market cap of $11.53 billion, a price-to-earnings ratio of 14.79, a price-to-earnings-growth ratio of 0.46 and a beta of 0.88. The stock’s 50-day moving average is $211.96 and its two-hundred day moving average is $183.05.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DVA. Barclays increased their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial cut their price objective on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Raymond James Financial set a $220.00 price objective on DaVita in a research report on Friday, August 7th. Finally, UBS Group raised their price objective on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $221.75.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.